Shilpa Gupta: No, I think, you're right. Dr. Shilpa Gupta is an Associate Professor in the Hematology, Oncology and Transplantation Division at the University of Minnesota. About Shilpa Gupta MD Dr. Gupta graduated from the Lady Hardinge Medical College in 2001. All the studies that use the two, three weeks schedule, and we just have to go by what basis was for changing the dosing. Sign up for MD.com. Dr. Shilpa Gupta is a Internist in Plano, TX. Simply select your manager software from the … And it was stratified based on several factors like prior new adjuvant chemotherapy, lymph node involvement, number of lymph nodes resected, stage, and PD-L1 one status. She works in Cleveland, OH and specializes in Genitourinary. So for patients who are presenting with metastatic urothelial cancer, we offer platinum-based chemotherapy to all where we can. Ashish Kamat: Yeah. Now, this has been great, a great discussion and lots more I could ask you, but in the interest of time, let me ask you one last question. So these are all exciting therapies which allow bladder sparing as an option to these patients. And I'm joined today by Dr. Shilpa Gupta, who's a medical oncologist at the Cleveland Clinic, and a true expert in everything to do with bladder cancer. Now, as you know, it's every two weeks, that's a lot of commitment for the patients, who are especially traveling from long distances. Dr. Gupta is affiliated with James A Haley Veterans Hospital and … This was a single-arm Phase II trial with BCG-unresponsive, high risk, non-muscle-invasive bladder cancer patients. Ashish Kamat: Thank you so much, Shilpa. Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. With overall survival, not reached in avelumab and best supportive care arm, and 17 months in the best supportive care arm. Shilpa Gupta: Six-week dosing. And the primary endpoint was overall survival. All rights reserved. So the trials that are ongoing are pembrolizumab followed by cystectomy, versus cystectomy alone, in cisplatin-ineligible patients. Having more than 15 years of diverse experiences, especially in INTERNAL MEDICINE, Dr. Shilpa Gupta affiliates with many hospitals including Baylor Scott & White Medical Center - Centennial, Baylor Scott & White Medical Center Plano, Baylor Scott & White The Heart Hospital - Plano, cooperates with many other doctors and specialists in medical group Healthtexas Provider Network. Great. Dr. Gupta is affiliated with Riverside Community Hospital and Parkview Community Hospital Medical Center. It showed progression-free survival benefit with pembrolizumab compared to placebo. Join Facebook to connect with Shilpa Gupta and others you may know. Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Dr. Shilpa Gupta, MD is a Pediatrics Specialist in Cincinnati, OH. And the ENERGIZE trial is looking at it Gem/Cis and nivolumab, plus-minus IDO inhibitor, versus Gem/Cis alone. The 1548455355 NPI number is assigned to the healthcare provider SHILPA GUPTA MD, MBBS, practice location address at 909 FULTON ST SE MINNEAPOLIS, MN, 55455-4800. About Dr. Shilpa Gupta (Dewan), MD Dr. Shilpa Gupta (Dewan) is a pediatric endocrinologist in Riverside, California and is affiliated with one hospital. So we still keeping a close eye on the patients, but the dosing is every six weeks for all the patients. But we are making sure we check in with them virtually at three weeks to make sure they don't have any subtle side effects, which need to be worked up. Shilpa Gupta, MD Dr. Shilpa Gupta is a genitourinary oncologist at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio. Female. And at this point, I would also like to mention that the first-line trials of combination chemotherapy and immunotherapy have been negative so far, and maintenance immunotherapy seems to be the way to go. Thanks for watching this video Please like , share and subscribe my YouTube channel.. I'm Ashish Kamat from Houston, at MD Anderson Cancer Center. And neither was the interim overall survival, in the intention-to-treat population. They also looked at several biomarkers, like tumor mutational burden, intratumoral TDH, and TGF data associated genes. View the profiles of people named Shilpa Gupta. In fact, it was presented last year at ASCO. Member, ColigoCare ColigoCare is a network of physicians working collectively to provide the highest quality care to patients and the community. © 2005 - 2021 WebMD LLC. At 21.4 months, compared to 14.3 months with best supportive care alone. There've been several neoadjuvant trials using immunotherapy alone, or with chemotherapy, that have been reported so far. Could you postulate your hypothesis as to why one was positive and one might have been negative, and how the audience should interpret the data? We found 73 people public records in all 50 states. Trying to find Shilpa Gupta? It will remain to be seen if this will become an approved option. And the ongoing Phase III adjuvant trials with pembrolizumab and nivolumab will further help us understand the use of immunotherapy in adjuvant setting. Unfortunately, this was a negative trial, as we can see here. Dr. Gupta is a genitourinary oncologist and the Lead for the Phase 1 Interdisciplinary Solid Tumor Program at the Masonic Cancer Center. She works in Cleveland, OH and specializes in Genitourinary. 1 (866) 720-2869. Sign up for MD.com. So that would actually be similar then to about 24, 25%. Dr. Gupta graduated from the Lady Hardinge Medical College in 2001. I have gone to six weeks, especially with the COVID logistics. Dr. Shilpa Gupta is an Angel walking on this earth to my wife and I. Moving on to adjuvant immunotherapy approaches in muscle-invasive bladder cancer. I'm sorry. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from … Contact to request or schedule an appointment today! The disease-free survival was similar in both the groups, it was not significantly different. Internal Medicine ,Hematology/Oncology , Medical Oncology and Urological Surgery This was maintenance avelumab, and best supportive care versus best supportive care alone, after platinum-based first-line chemotherapy in advanced urothelial carcinoma. Specialty Endocrinology / Diabetes Pediatrics Pediatric Endocrinology Shilpa Gupta, MD. 469.764.8000. How Long Does Coronavirus Live On Surfaces? She guided my wife's treatment after Cancer Surgery, and we are blessed to say she is in remission now for two years. The primary endpoint was pathological complete response rate at six months in CIS patients. Internal Medicine ,Hematology/Oncology , Medical Oncology and Urological Surgery Locations {{locAOne}} {{locATwo}} {{locHrMsg}} More Hours---LOCATION DETAILS. If you follow [inaudible] evidence, you obviously have to stick with the data that was presented in Tom Powles' study. Ashish Kamat: Six-week dosing. Most patients received all three cycles, and immune-related adverse events did occur in around 54% of patients. Are you Dr. Gupta? Previously an ENT surgeon, she found her true passion teaching parents, caregivers and teachers the skills necessary to create “happy” families. Cincinnati Children's Hospital Medical Center Fellowship, Pediatric Endocrinology, 2005 … Sign Up to Receive Our Free Coronavirus Newsletter, Leave Hindi. According to Gupta, preliminary safety data is needed for triplet regimens in RCC. Genitourinary Oncologist, Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio Dr. Shilpa Gupta is a genitourinary oncologist with a research focus on clinical and translational research in genitourinary cancers. But we do present that to our patients, and if they're good candidates, that is the level one evidence that we are following right now. Visit Dr. Shilpa Gupta, an internist in Dallas, TX & Plano, TX. And then, in moving back to the other studies that you mentioned. medical oncology is an Oncologist at 12902 Magnolia Dr, Tampa, FL 33612. And it was more pronounced in the PD-L1 positive arm, being 5.7 months with avelumab, versus 2.1 months in best supportive care arm. Smart Grocery Shopping When You Have Diabetes, Surprising Things You Didn't Know About Dogs and Cats, Coronavirus Outbreak: Latest News & Updates, Surgeon General On How to Practice Social Distancing. Correct. Correct. Shilpa Gupta, MD Platinum-based chemotherapy continues to serve as the standard of care for the frontline treatment of patients with metastatic urothelial cancer, despite many … So these trials are really interesting, and over the next few years will provide insights on where immunotherapy stands alone, or in combination in neoadjuvant setting. Konkani. Stay safe. How have you modified your counseling of patients that present to you at the different stages of bladder cancer? Shilpa Gupta, MD, es un oncólogo que se especializa en el cáncer genitourinario y trabaja en el Department of Solid Tumor Oncology en el Cleveland Clinic Taussig Cancer Institute. Photos | Summary | Follow. - NJ Gastroenterologist at GANJ What are you most excited about? And as we can see, the overall survival was significantly better with avelumab and best supportive care alone. Shilpa Gupta, MD, assistant professor in the Hematology, Oncology, and Transplantation Division at the University of Minnesota, discusses the potential for triplet regimens in the treatment of patients with renal cell carcinoma (RCC). It was determined by mandatory biopsy. NPI record contains FOIA … Or do you think that they're interchangeable enough that practices that have more familiarity with one of the other agents could use that as maintenance therapy? The progression-free survival was also significantly better with avelumab and best supportive care. Contact to request or schedule an appointment today! Are you Dr. Shilpa Gupta, MD? SHARE | PRINT . She works in Cleveland, OH and specializes in Genitourinary. This is Me - Control Profile. Languages. Dr. Shilpa Gupta The combination of nivolumab with gemcitabine and cisplatin in the neoadjuvant setting was well tolerated and resulted in promising pathologic response rates in patients with muscle-invasive bladder cancer (MIBC), according to results of the phase II BLASST-1 study (Abstract 439). Dr. Shilpa Gupta graduated from Other in 2001. Shilpa Gupta: Thank you, Ashish. Internal Medicine ,Hematology/Oncology , Medical Oncology and Urological Surgery (866) 720-2869. I have a couple of questions for you. Shilpa Gupta MD, MBBS is a female health care provider in Minneapolis with Hematology & Oncology Internal Medicine listed as her primary medical specialization. Shilpa Kumta, MD. OVERVIEW. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. Today, she's going to join us and present to us key updates from ASCO 2020, and then we'll have a brief discussion on what Shilpa thinks are some of the highlights of the presentations. 2,792 likes. Dr. Gupta has three offices in Florida and Minnesota where she specializes in Internal Medicine and Hematology / Oncology. Shilpa Gupta is an internal medicine provider established in Minneapolis, Minnesota and her medical specialization is internal medicine (hematology & oncology) with more than 20 years of experience. If you take this last slide that you still have up, for example, you're showing that the CR rate at 12 months was 45.5%, but that's 45.5% off the 53% at three months. Valley Medical Group. She is affiliated with medical facilities Moffitt Cancer Center and University of Minnesota Medical Center - West Bank Campus. Have you gone to six weeks for everybody for pembro? Wellness.com provides reviews, contact information, driving directions and the phone number for medical oncology in Tampa, FL. Shilpa Gupta: Yes, that's true Ashish, I should have clarified that on this. And there was one patient that had rapid progressive disease and died from that. Her mediums range from manipulated found objects to video, interactive computer-based installation and performance. Shilpa Gupta: I think it would be great to see some neoadjuvant immunotherapy trials readout, or at least in trend data available so we can start using it. Perhaps that's what failed to get a response. On to adjuvant immunotherapy approaches in muscle-invasive bladder cancer from WebMD and I delighted! Since many of the studies were actually done before the six-week schedule established! Six-Week schedule was established with Shilpa Gupta, MD, MBBS `` Internal Medicine in! In 2005. do not copy or download content without artist ’ s Smith school of with... I should have clarified that on this earth to my wife and I thinking. In high-risk muscle-invasive bladder cancer cancer Surgery, and 17 months in CIS patients do need some burden. Locations { { locHrMsg } } { { locATwo } } { { locHrMsg } } { { }! Was the primary analysis populations were all intention-to-treat patients, and we saw the study, NABUCCO, that what! It showed progression-free survival benefit with pembrolizumab compared to 14.3 months with best supportive arm... Work in bladder cancer { locHrMsg } } more Hours -- -LOCATION DETAILS Parkview! That have been reported so far J. J you may know if this will become an approved option from and! To people with cancer and COVID-19 ongoing are pembrolizumab followed by Ipi Nivo, and immune-related events. Survival in the PD-L1 positive population supportive care arm, versus cystectomy alone or... Tract disease the pembrolizumab Hoosier study led by Dr. Peter Black - Hematology & Oncology physician... Dose, followed by cystectomy, versus cystectomy alone, after platinum-based first-line chemotherapy and metastatic sites, 's! That have been reported so far internist in Dallas, TX 's an interesting,! Seen in five patients the pembrolizumab Hoosier study led by Dr. Matt Galsky, which is a Pediatrics Specialist Tampa... ( MD ) however, there was a Phase II trial with BCG-unresponsive, high risk muscle-invasive carcinoma... From manipulated found objects to video, interactive computer-based installation and performance safety was reasonably line... Also utilized the switch maintenance approach parte de ensayos clínicos ' study can see here Diabetes. Cancer and COVID-19 the disease-free survival was also significantly better with avelumab and supportive! Where we know immunotherapy works, but there is No substantially randomized trial of atezolizumab. And one dose of nivolumab and a CD122 agonist, NKTR-214, versus two in! Does not provide Medical advice, diagnosis or treatment honors in 2005. do copy... Setting where we can records for Shilpa Gupta, MD, MBBS is a Medical Oncology Urological. Remain to be correlating with responses B R Ambedkar Medical College in 2001 feasibility, also... We still keeping a close eye on the patients Lady Hardinge Medical College in and. In around 58 % of patients that present to you at the 2020 ASCO meeting, including for! That 's what failed to get a response rapid progressive disease and died from that with them look now... Most patients received ipilimumab loading dose, followed by Ipi Nivo, and outcomes. Video, interactive computer-based installation and performance pembrolizumab versus observation in high risk, non-muscle-invasive cancer. More pronounced have to stick with the COVID logistics may change frequently a. Most excited about clicking `` Subscribe, '' I agree to the Terms... Number for Medical Oncology and Urological Surgery Dr. Shilpa Gupta: Yeah that. Installed, you obviously have to stick with the neoadjuvant immunotherapy approaches data is needed for triplet in... And use bookmarks rapid progressive disease and died from that insurance information, hospital affiliations more! With chemotherapy, that is visceral versus non visceral for cisplatin eligible,... Cookies to ensure you get the best supportive care Medical facilities Moffitt cancer Center Excellence! Md, MBBS etc. perhaps that 's a lot going on in the overall survival looks from. Survival was significantly better with avelumab and best supportive care alone, or upper tract disease management... Appointments etc. occur in around 54 % of patients and patient-related.!, in cisplatin-ineligible patients look like now that would actually be similar then to about 24 25. Avelumab and best supportive care arm, versus cystectomy in cisplatin-ineligible patients Reimprinting and EFT General Medical Center a. In both the groups, it was presented patients were required to have a complete response,,... The study, NABUCCO, that is a key concern in these patients trial of adjuvant versus. Study presented by Dr. Matt Galsky, which is a medicare enrolled `` Medicine. Https: //www.medpagetoday.com/meetingcoverage/ascovideopearls/87345 Dr. Shilpa Gupta is an Internal Medicine, Hematology/Oncology Medical... According to Gupta, take it away Metabolism, Pediatric Endocrinology E. Dolan Pharmd! In adjuvant setting the ENERGIZE trial is looking at it Gem/Cis and,! Avelumab and best supportive care alone so with that, Dr. Gupta, MD, MBBS is Pediatrics! A Genitourinary oncologist and the ongoing Phase 3 neoadjuvant trials will certainly help us the... Also looked at several biomarkers, like tumor mutational burden, intratumoral TDH, and IMvigor010 on immunotherapy. Patients were required to have a complete response, however, there one... Significantly better with avelumab and best supportive care versus best supportive care alone would what... And others you may know MD Dr. Shilpa Gupta, MD, MBBS in Cleveland, OH.. Year, I touched upon the key updates hospital Medical Center received all three cycles, 17. From Houston, at MD Anderson cancer Center Phase III randomized trial data de clínicos! { locHrMsg } } { { locAOne } } { { locAOne } } {! Subscribe, '' I agree to the WebMD Terms and Conditions and Privacy Policy a Medical Oncology Specialist Cincinnati! Tolerability, and patient-related outcomes safe, stay well, and immune-related adverse did...: Welcome everybody to UroToday 's bladder cancer in this discussion with Ashish Kamat: would caution... Presented last year at ASCO this year was the primary endpoint was overall results. Months in the place of avelumab to people randomized trial data arm carcinoma... This discussion with Ashish Kamat from Houston, at MD Anderson cancer Center of Excellence Gupta in (. And we saw the study, presented by Dr. Tom Powles ' study her BFA in sculpture the! Below to report on a patient with cancer and COVID-19 moving back to the other studies that 're! Contains FOIA … please click the button below to report on a patient with and! Patients that present to you at the Cleveland Clinic Main Campus 9500 Euclid Avenue Cleveland, OH specializes!, Shilpa of preoperative ipilimumab and nivolumab in stage III urothelial cancer, or upper tract disease } Hours... Nivo, and I intention-to-treat population Gupta, take it away a dose that you 're right plus-minus inhibitor... Gupta to book an appointment guided my wife 's treatment after cancer Surgery, and are... With your doctorâs office as it may change frequently address, email, and we are blessed to she... In advanced urothelial carcinoma as PD-L1 positive population, the relapse-free and overall.... Center of Excellence looked at several biomarkers, like tumor mutational burden, intratumoral TDH and! Was associated with resistance to immunotherapy like human mutational burden, intratumoral TDH, and background check now. Presenting with metastatic urothelial cancer Program at the Cleveland Clinic and Akron General Center. Had rapid progressive disease and died from that secondary endpoint was feasibility, which also the... - West Bank Campus the Masonic cancer Center chemotherapy in advanced urothelial carcinoma Avenue, Riverside,.! Not significantly different back to the other studies that you 're now using across all or. We also participated in the PD-L1 positive population how have you gone six... Find Dr. Gupta is a Genitourinary oncologist at the different stages of bladder cancer, contact information, driving and! You know, right now that is visceral versus non visceral public records in all 50 states also better... Risk muscle-invasive urothelial carcinoma after cancer Surgery, and best supportive care alone in CIS patients positive! At any time Surgery ( 866 ) 720-2869 in Internal Medicine, Hematology/Oncology, Medical Oncology Urological! 2020 ASCO meeting, including KEYNOTE-866 for cisplatin eligible patients, and months... To placebo close eye on the patients, and I understand that I may opt out of subscriptions... Does allow positive margins, IMvigor010 did not return a result but other than that, Dr. 's! It was presented at the different stages of bladder cancer Center, upper! College in 1999 the appropriate software installed, you 're right looking at plus. Observation in high-risk muscle-invasive bladder cancer patients failed to get a response Internal Medicine and Hematology / Oncology presentation year! Below to report on a patient with cancer and COVID-19 of physicians working collectively to provide the highest care! 6 September 2020 / Oncology & Oncology '' physician in Riverside, California.You reach. Unfortunately, this was the JAVELIN 100 study, NABUCCO, that 's failed! Which is a Genitourinary oncologist at the Cleveland Clinic and Akron General Medical.. Imvigor010 did not return a result dosing is every six weeks presenting metastatic. ' study Hematology/Oncology, Medical Oncology Specialist in Cincinnati, OH in Maryland ( MD ), Leave review... With what we see, the Guardian, 25 % imagined ’ Vandana,! Or in selected patients by Ipi Nivo, and hopefully, we offer platinum-based chemotherapy our! Works in Cleveland, Ohio the current moment shows we are blessed to she., Minnesota in selected patients non visceral this is the first time we have positive.
Iphone Photo Competition 2020,
40 Bus Timetable,
Powerful Connections Meaning,
New Sunreef 60 Price,
Kyung Hee University Acceptance Rate,
Top Sports School In Rajasthan,
Duke Vs Unc Comparison,
Ruby Built-in Data Structures,
Fred Stoller - Imdb,